BCR: a new target in resistance mediated by BCR/ABL-315I?

類似資料

• Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
  著者:: Mian, Afsar Ali, 等
  出版事項: (2021)
• Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
  著者:: Mian, Afsar Ali, 等
  出版事項: (2012)
• The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia.
  著者:: Anahita Rafiei, 等
  出版事項: (2015-04-01)
• The Functional Interplay Between the t(9;22)-Associated Fusion Proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome-Positive Acute Lymphatic Leukemia
  著者:: Rafiei, Anahita, 等
  出版事項: (2015)
• Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism
  著者:: Khateb, Mamduh, 等
  出版事項: (2012)